CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
Lastacaft ® +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02308501
NCT02308501Phase 4Completed
CompareCT.gov

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy

ORA, Inc.·interventional·Posted Dec 4, 2014·Updated Mar 18, 2021

In Brief

A Phase 4 clinical trial evaluating Lastacaft ® and Tears Naturale ® (Placebo) for Allergic Conjunctivitis. Completed, enrolled 25 participants.

Detailed Summary

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft ® as Measured by In-Vivo Confocal Microscopy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 4, 2014
Enrollment StartDec 1, 2014
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.6 years ago

Interventions

Lastacaft ®drug

Tears Naturale ® (Placebo)drug